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1 Contrary to established metabolic pattern, a recent
investigation of NNK metabolism produced in rat urine
higher levels of 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyri-
dyl)-1-butanol (NNAL) than their N-oxides, suggesting
that reconversion of N-oxides could occur after urine
formation.
2 To verify the possible role of bacteria in the reduction
of NNK-N-oxide and NNAL--oxide to their respective
parent compounds, NNK and NNAL, in smokers with
urinary tract infection (UTI), the -oxides were isolated
from the urine of rats treated with [5-3H]NNK and
individually incubated at 37&deg;C with ten bacterial species
in sterile human urine under different pH regimens. After
incubation with the bacteria, aliquots of culture media
were analyzed by high pressure liquid chromatography
(HPLC) with radiochemical detection.
3 Escherichia coli, Enterobacter cloacae, Klebsiella
pneumoniae and Proteus mirabilis possessed varying
capacity to regenerate NNK and NNAL from their N-
oxides while others showed no detectable reductive
capability within 24 h.
4 This result constitutes the first experimental evidence
that in tobacco users with concomitant UTI, bacterial
regeneration of the procarcinogenic NNK and NNAL from
their N-oxides could occur in the bladder leading to
increased carcinogen burden in these individuals.
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Introduction
The tobacco-specific nitrosamine 4-(methylnitros-
amino)-1-(3-pyridyl)-1-butanone (NNK) is consid-
ered to play a major role in the induction of lung
cancer in cigarette smokers., Independent of route
of administration, NNK is highly carcinogenic to the
rodent lung, inducing adenocarcinoma and squa-
mous cell carcinoma in rats, hamsters or mice. In
addition, tumours of the nasal mucosa, liver and
exocrine pancreas have been observed in rats
treated with NNK. 4-(Methylnitrosamino)-l-(3-pyr-
idyl)-1-butanol (NNAL), a major metabolite of NNK
induces tumours in the lung of rats and mice and is
an especially potent carcinogen for the exocrine
pancreas in rats.1
NNK and its reduction product, NNAL are
procarcinogens requiring metabolic activation be-
fore they can react with cellular components.’
Experiments utilizing human cell tissues, cells
expressing cytochrome P450 isoenzymes and a
variety of laboratory animals have demonstrated
that metabolism of NNK involves three principal
pathways, namely, carbonyl reduction, pyridine N-
oxidation and a-hydroxylation (Figure 1). Carbonyl
reduction of NNK produces NNAL while a-hydro-
xylation of both NNK and NNAL produces 4-oxo-(3-
pyridyl) butyric acid (keto acid) and/or 4-hydroxy-
(3-pyridyl) butyric acid (hydroxy acid). These acids
constitute the major urinary metabolites in experi-
mental animals dosed with NNK.3-5 Both NNK and
NNAL may undergo pyridine N-oxidation to pro-
duce NNK-N-oxide and NNAL-N-oxide respec-
tively. NNAL is a substrate for glucuronyl
transferase leading to the formation of one (rats
and mice) or two (patas monkeys, humans) stereo
isomers of [4-(methylnitrosamino)-1-(3-pyridyl)but-
1-yl]-/3-O-D-glucopyranosiduronic acid (NNAL-
Glu).3·4,6,~ Essentially, glucuronidation of NNAL
and pyridine N-oxidation of both NNAL and NNK
are considered to be a detoxification process.2 These
reports demonstrated that beside the acids, at low
NNK doses, N-oxides rather than the parent
compounds should be the principal urinary meta-
bolites.
However, in a recent experiment, it was dis-
covered that some rats administered low doses of
[5-’HINNK produced in their urine higher levels of
NNK and NNAL than the N-oxides.8 This observa-
tion led us to propose that other extraneous factors,
possibly of microbial origin must be responsible for
the anomaly. To verify this hypothesis, purified
 at LMU Muenchen on May 16, 2013het.sagepub.comDownloaded from 
330
Figure 1 Metabolism of NNK.
NNK-N-oxide and NNAL-N-oxide were incubated
in urine with bacteria known to be associated with
diseases of human urino-genital system. In this
article, we present the first evidence that some
bacterial species as present in the bladder of
patients with urinary tract infection (UTI) possess
some capacity to reduce N-oxides of TSNA to their
parent procarcinogenic entities, NNK and NNAL,
thus increasing carcinogen burden in these indivi-
duals. 
Materials
Reagents and solvents were obtained from commer-
cial sources in analytical (Sigma Chemie GmbH,
Taufkirchen, Germany) or HPLC grade (Merck,
Darmstadt, Germany). [5-,H]NNK (specific activity,
2.89 Ci/mol) was obtained from Chemsyn (Lenexa,
USA). NNK-N-oxide and NNAL-N-oxide were
obtained from the urine of [5-’HINNK-treated ratS8
by repeated HPLC purification and freeze-drying.
The identity of the N-oxides was confirmed by co-
chromatography with NNK metabolite standards
generously donated by Dr D Hoffmann (American
Health Foundation, Valhalla, NY).
Ten microbial strains, Enterobacter cloacae,
Pseudomonas aeruginosa, Klebsiella pneumoniae,
Escherichia coli, Proteus mirabilis, Staphylococcus
epidermidis, Staphylococcus aureus, Streptococ-
cus viridans, Enterococcus spp. and Candida
tropicalis, 1010 counts in 1 mL of physiological
saline from the stocks of the Max-von Pettenkofer
Institute of Hygiene and Medical Microbiology,




Morning urine was collected from an apparently
healthy human subject who neither consumes
tobacco products nor drinks alcohol. The pH was
noted and the urine was centrifuged at 3000 r.p.m.
for 10 min. The supernatant was filtered through a
sterile 0.45 pm membrane filter (Millipore, Es-
chborn, Germany) into three sterile containers.
The pH of one portion was adjusted to 8 while
another was adjusted to 6. The pH of the third
portion was left unadjusted at 6.9.
Sterile urine (1 mL for each pH level) was
incubated in a water bath at 37°C with about
200 pL of the substrate solution corresponding to
approximately 33.6 pmol (215 000 d.p.m.) NNK-N-
oxide and 18.7 pmol (120 000 d.p.m.) NNAL-N-
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oxide respectively, and 10 pL of bacterial inoculum
(count: 108) At the initial screening stage, the
mixture was incubated at 37°C for 24 h before
analysis. In subsequent experiments, aliquots of
the incubation media were withdrawn for HPLC
analysis after 3, 6 and 9 h of incubation. To exclude
formation of NNK and NNAL in the culture media,
samples of blank urine were run as control without
added bacteria.
HPLC analysis
Aliquots of the incubation mixture 0.3 - 0.4 mL
were stabilized with 0.1 mL phosphate buffer,
pH 7.2 (200 mM for normal urine and 500 mM for
acidic or basic mixtures). After centrifugation at
3000 r.p.m. for 10 min the supernatant was ana-
lyzed immediately or stored at - 20°C.
Samples were chromatographed on a
4.6 x 250 mm LiChrosorbR RP18 selectB column
(Merck, Darmstadt, Germany) by elution with a
gradient of 100% A for 0.5 min, linear to 80% A/
20% B in 20 min and linear to 20% A/80% B in
20 min (A=20 mM phosphate buffer, pH 7.2;
B=acetonitrile) at a flow rate of 0.7 mL/min.3H was
detected by solid phase radioactivity monitoring
(Ramona, Raytest, Straubenhardt, Germany). Radio-
active metabolites were identified by co-chromato-
graphy with unlabeled reference compounds using
UV detection at 254 nm (UVD 160, Gynkotek,
Gemering, Germany).
Calculations
The concentration of the N-oxides incubated and
the TSNA regenerated by bacteria were calculated
based on the following relationship: Ten urine
samples of NNK-treated rats with known amounts
of radioactivity (1034-2253 d.p.m./500 /tL) pro-
duced a total area of 888 - 3 791 units. The average
d.p.m./area unit was 87 ± 7. Based on the specific
activity of [5-’HINNK one area unit corresponds to
13.54 attomol of NNK.
Results .
After 24 h incubation, only Escherichia coli, En-
terobacter cloacae, Klebsiella pneumoniae and
Proteus mirabilis produced detectable levels of
NNK and NNAL under our experimental condition.
These bacteria were therefore selected for further
investigation while Staphylococcus aureus, Staphy-
lococcus epidermidis, Streptococcus viridans, Can-
dida tropicalis, Enterococcus spp and Pseudomonas
aeruginosa which at this stage regenerated no
TSNA were qualitatively considered negative
(Tables 1 and 2).
Figure 2 illustrates the complete reconversion of
NNK-N-oxide and NNAL-N-oxide by 24 h incuba-
tion of urine with Proteus mirabilis. Whereas the
control urine without added bacteria had a single
peak corresponding to NNK-N-oxide or NNAL-N-
oxide peak (A,B), the test (C,D) had a peak with
retention times corresponding respectively to re-
ference NNK and NNAL. The identity of the
regenerated [5-’HINNK and NNAL was confirmed
by co-chromatography of these radioactive metabo-
lites with unlabelled reference compounds. This
procedure permitted simultaneous monitoring and
Table 1 Qualitative and quantitative studies of NNK formation from NNK-N-oxide by bacteria at different pH and incubation period
-ve= No formation of NNK after 24 h incubation of normal urine with NNK-N-oxide during qualitative screening.
+ve= Formation of NNK after 24 h incubation of normal urine with NNK-N-oxide during qualitative screening; these bacteria were
selected for quantatitive studies.
nd=Not detected.
- = Not determined.
* For definition of pH conditions see methods.
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Table 2 Qualitative and quantitative studies of NNAL formation from NNAL-N-oxide by bacteria at different pH and incubation period
-ve= No formation of NNAL after 24 h incubation of normal urine with NNAL-N-oxide during qualitative screening.
+ve= Formation of NNAL after 24 h incubation of normal urine with NNAL-N-oxide during qualitative screening; these bacteria were




* For definition of pH conditions see methods.
comparison of the unlabelled compounds by UV
detection at 254 nm (UVD 160, Gynkotek, Gemer-
ing, Germany) and the regenerated radioactive
compounds by solid phase radioactive monitoring.
After 3 h incubation, detectable levels of NNK
were produced by Escherichia coli, Klebsiella
pneumoniae and Proteus mirabilis but not Enter-
obacter cloacae. The highest rate of reconversion
was found in Proteus mirabilis at basic pH.
Generally, alkaline pH was most favourable for the
regeneration of NNK, while acidic pH was the least
favoured. The effect of pH appears to be least
dramatic on the regeneration of NNK by Klebsiella
Figure 2 Reduction of NNK-N-oxide (A,C) and NNAL-N-oxide
(B,D) by Proteus mirabilis. HPLC radiochromatograms of human
urine (pH 6.9) after 24 h incubation without (A,B) or with (C,D)
added bacteria (count: lo’/ml).
pneumoniae than in any other species found to
possess reductive capacity on NNK-N-oxide (Table
1).
Table 2 shows the rate of regeneration of NNAL
by tested bacterial species. Like in the reduction of
NNK-N-oxide, the bacteria are most efficient at
reducing NNAL-N-oxide at alkaline pH and least
efficient at acidic pH except in the case of
Enterobacter cloacae where the trend appears to
be reversed.
Discussion
Nitrosamine formation by bacteria in the bladder
has been hypothesized to be an associated factor for
cancer of the bladder in individuals with UTL9-11
Previous studies have established that Escherichia
coli, Klebsiella pneumoniae and Proteus mirabilis
are some of the bacterial species that may either
catalyze nitrosation of secondary amines or are
associated with UTI in which N-nitroso compounds
have been detected in the urine of patients.&dquo;-13 The
present study has demonstrated that these same
bacterial species also possess some capacity to
regenerate NNK and NNAL from their precursor
N-oxides. To our knowledge, this is the first report
on the possible involvement of bacteria in the
reduction of N-oxides of TSNA which are primarily
considered to be detoxification products, back to
their procarcinogenic parent compounds.
Although the bacterial reduction of N-oxides of
TSNA has not been previously reported, it is not an
unexpected observation. The role of the gut flora in
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the reduction of N-oxide drugs is well established. 14
Regeneration of nicotine and cotinine from corre-
sponding N-oxides has been repeatedly reported to
occur in vivo as well as in vitro.l5-1’ The reasons for
the varying pH-dependent capacities of different
bacteria to regenerate NNK and NNAL from their N-
oxides are not clear and require further investiga-
tions. The highest rate of regeneration of the two
compounds was observed in Proteus mirabilis at
alkaline pH. In general, the bacteria tested pos-
sessed higher capacity to reconvert NNK-N-oxide to
NNK than reconversion of NNAL-N-oxide to its
parent compound.
The low concentrations used in the present
investigation, 15-40 nmol/L, are still higher than
the concentrations which could be expected to
occur in urine of a heavy smoker. NNK uptake is
estimated to be on average 300 ng/cigarette.18
Assuming a 24 h uptake of 12 ~g NNK (40 cigar-
ettes/day), and a percentage of N-oxide metabolites
of maximally 15% as observed in patas monkeys,4 4
this would give a concentration of N-oxides in urine
of -1.8 nmol/L.
NNK and NNAL are powerful carcinogens with
the lung as a major target. Therefore, bacterial
reduction of N-oxides of these TSNA to their
procarcinogenic parent compounds may have some
implications: In tobacco users with UTI, regenera-
tion of NNK and NNAL could mean exposure of the
bladder walls to active forms of the carcinogens
through metabolic activation. Whether the bladder
tissue has the capacity to activate NNK and NNAL
requires further investigation. The second possibi-
lity is that the regenerated NNK and NNAL could be
absorbed by the bladder tissues and recirculated
through blood to site(s) where they are re-metabo-
lized to produce more ultimate carcinogens. Ability
of bladder tissues to absorb other N-nitroso com-
pounds into the blood stream has been demon-
strated in the rat.9 In either case, tobacco user with
UTI stands higher burden of ultimate carcinogens
than the healthy user and might be at higher risk to
develop tobacco-related cancers.
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none ; NNAL, 4-(methylnitrosamino)-l-(3-pyridyl)-i-
butanol ; NNK-N-oxide,4-(methylnitrosamino)-1-(3-pyr-
idyl-N-oxide)-1-butanone; NNAL-N-oxide,4-(methylni-
trosamino)- 1-(3-pyridyl-N-oxide)- I -butanol; HPLC,
high pressure liquid chromatography; TSNA, tobacco-
specific nitrosamines; UTI, urinary tract infection.
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